ORLANDO, FLA.—A novel oral formulation of azacitidine produced a highly significant improvement in overall survival (OS) when administered as a maintenance therapy to patients with acute myeloid leukemia (AML) in first remission.
“The OS improvement was observed in a broad range of patients with AML, including those with adverse cytogenetics,” reported Andrew H. Wei, MBBS, PhD, a clinical and research hematologist with dual appointments at Alfred Hospital and Monash